Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke

Genetic Testing

Volumn 12, Issue 3, 2008, Pages 443-451

  Kucukarabaci, Banu ^a   Gunes, Hasan Veysi ^a   Ozdemir, Gazi ^a   Cosan, Didem ^a   Ozbabalik, Demet ^a   Dikmen, Miris ^b   Degirmenci, Irfan ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b ANADOLU UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAI 1 GENE; POLYMERASE CHAIN REACTION; STROKE;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 50649084763     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2008.0025     Document Type: Article

References (30)

1. Balkan S (2005) Serebrovasküler hastaliklar. Ankara, Güneş Kitabevi, pp 1-2.
2. Castello R, Espana F, Vazquez C, et al. (2006) Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 117:487-492.
3. Catto AJ, Carter AM, Stickland M, et al. (1997) Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 77:730-734.
4. Chong N, Codd V, Chan D, Samani NJ (2006) Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference. FEBS Lett 580:4469-4472.
5. Ding J, Nicklas BJ, Fallin MD, et al. (2006) Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but nor with myocardial infarction or stroke. Am Heart J 152:1109-1115.
6. Dobrovolsky AB, Titaeva EV (2002) The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry 67:99-108.
7. Eikelboom JW, Hankey GJ, Anand SS, et al. (2000) Association between high homocyst(e)inemia and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 31:1069-1075.
8. Hajat C, Dundas R, Stewart JA, et al. (2001) Cerebrovascular risk factors and stroke subtypes: differences between ethnic groups. Stroke 32:37-42.
9. Harmon DL, Doyle RM, Meleady R, et al. (1999) Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 19:208-211.
10. Henry M, Chomiki N, Scarabin Y, et al. (1997) Five frequent polymorphisms of the PAI-1 gene. Arterioscler Thromb Vasc Biol 17:851-858.
11. Hoekstra T, Geleijinse JM, Kluft C, et al. (2003) 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 34:2822-2828.
12. Jeng JR (2003) Association of PAI-1 gene promoter 4G/5G polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension. Am J Hypertens 16:290-296.
13. Johansson L, Jansson J, Boman K, et al. (2000) Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31:26-32.
14. Jood K, Ladenvall P, Wolf A, et al. (2005) Fibrinolytic gene polymorphism and ischemic stroke. Stroke 36:2077-2081.
15. Kitamura Y, Okumura K, Imamura A, et al. (2004) Association of plasminogen activator inhibitor-1 4G/5G gene polymorphism with variations in the LDL particle size in healthy Japanese men. Clin Chim Acta 347:209-216.
16. Kristensen B, Malm J, Nilsson TK, et al. (1998) Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. Stroke 29:2261-2267.
17. Lindgren A, Lindoff C, Norrving B, et al. (1996) Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 27:1066-1071.
18. Liu M, Wu B, Wang W, et al. (2007) Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 6:456-464.
19. Madonna P, Stefano V, Coppola A, et al. (2002) Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 33:51-56.
20. Margaglione M, Cappucci G, Colaizzo D, et al. (1998) The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary disease. Arterioscler Thromb Vasc Biol 18:152-156.
21. Margaglione M, Grandone E, Vechione G, et al. (1997) Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Throm Vasc Biol 17:2082-2087.
22. Morita H, Kurihara H, Tsubaki S, et al. (1998) Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 18:1465-1469.
23. Nordenhem A (2006) The fibrinolytic enzyme system: new markers of potential interest in cardiovascular disease. Stockholm, Karolinska Institutet, pp 1-41.
24. Roest M, Schouw YT, Banga JD, et al. (2000) Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 101:67-70.
25. Schulz UGR, Rothwell PM (2003) Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 34:2050-2059.
26. Somay G, Topaloǧlu P, Somay H, et al. (2006) Cerebrovascular risk factors and stroke subtypes in different age groups: a hospital-based study. Turk J Med Sci 36:23-29.
27. Tan NC, Venketasubramanian N, Saw S, Lian H (2002) Hyperhomocyst( e)inemia and risk of ischemic stroke among young Asian adults. Stroke 33:1956-1962.
28. Wiklund P, Nilsson L, Ardnor SN, et al. (2005) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 36:1661-1665.
29. Wiwanitkit V (2006) Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and preeclampsia: an appraisal. Arch Gynecol Obstet 73:322-324.
30. Yilmaz E, Akar E, Akar N (2004) Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thromboembolic patients with and without prothrombin 20210 G-A. Turk J Haematol 21:83-86.